These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 2091686)
1. Two years experience of daily self-administered subcutaneous erythropoietin. Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M Blood Purif; 1990; 8(5):268-71. PubMed ID: 2091686 [TBL] [Abstract][Full Text] [Related]
2. [Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin]. Boratyńska M; Mazanowska O; Szewczyk Z Pol Merkur Lekarski; 1996 Nov; 1(5):329-31. PubMed ID: 9273209 [TBL] [Abstract][Full Text] [Related]
4. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Jensen JD; Madsen JK; Jensen LW Eur J Clin Pharmacol; 1996; 50(3):171-7. PubMed ID: 8737755 [TBL] [Abstract][Full Text] [Related]
5. Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients. Trakarnvanich T; Thitiarcharkul S J Med Assoc Thai; 2004 Sep; 87(9):1041-7. PubMed ID: 15516004 [TBL] [Abstract][Full Text] [Related]
6. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration]. Zehnder C; Blumberg A Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110 [TBL] [Abstract][Full Text] [Related]
7. Erythropoietin response and route of administration. Taylor JE; Belch JJ; Fleming LW; Mactier RA; Henderson IS; Stewart WK Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210 [TBL] [Abstract][Full Text] [Related]
8. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998 [TBL] [Abstract][Full Text] [Related]
9. Treatment of the anemia with human recombinant erythropoietin in CAPD patients. Miranda B; Selgas R; Riñon C; Fernandez-Zamorano A; Borrego F; Ortuño F; Lopez-Revuelta K; Torre A; Sanchez Sicilia L Adv Perit Dial; 1990; 6():296-301. PubMed ID: 1982831 [TBL] [Abstract][Full Text] [Related]
10. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis]. Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD. Icardi A; Paoletti E; Molinelli G Adv Perit Dial; 1990; 6():292-5. PubMed ID: 1982830 [TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum. Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507 [TBL] [Abstract][Full Text] [Related]
13. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Lai KN; Lui SF; Leung JC; Law E; Nicholls MG Nephron; 1991; 57(4):394-400. PubMed ID: 1828543 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Nielsen OJ Pharmacol Toxicol; 1990 Feb; 66(2):83-6. PubMed ID: 2315268 [TBL] [Abstract][Full Text] [Related]
15. Correction of anemia using self-administered daily subcutaneous erythropoietin in uremic patients on continuous ambulatory peritoneal dialysis. Li PK; Leung CB; Lui SF; Leung JC; Shek AC; Lai KN Int J Artif Organs; 1993 Jul; 16(7):510-4. PubMed ID: 8370605 [TBL] [Abstract][Full Text] [Related]
16. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study]. Ruedin P; Stoerman C; Pechère-Bertschi A; Leski M Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of low dose erythropoietin: a possible advantage of high flux hemodialysis. Depner TA; Rizwan S; James LA ASAIO Trans; 1990; 36(3):M223-5. PubMed ID: 2252662 [TBL] [Abstract][Full Text] [Related]
19. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients. Lui SF; Wong KC; Li PK; Lai KN Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366 [TBL] [Abstract][Full Text] [Related]
20. [Effect of recombinant human erythropoietin on renal function in predialysis patients]. Tsubakihara Y; Itoh T; Kitamura E; Okada N; Nakanishi I; Iida N Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):557-63. PubMed ID: 1920935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]